Clinical characteristics of renal cell carcinoma: Five years review from a tertiary hospital in Eastern India

Ray, Rajendra Prasad; Mahapatra, Rajkumar Singha; Khullar, Shivani; Pal, Dinesh; Kundu, Anup Kumar

doi:10.4103/0019-509x.180851

Cited by 16 publications

(20 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RCC is classified into several types: clear cell type, granular cell type, mixture cellularity, and undifferentiated cell type [10]. Based on literature searches, multiple pathogenic factors are related with RCC malignancy, including obesity, eating habits, smoking, drinking, and long-term exposure to radioactivity [11]. Surgery, radiotherapy, chemotherapy, and immunotherapy are by far most commonly used therapeutic methods of RCC, but they have a small curative effect and a negative impact on RCC patients [12].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma

et al. 2017

View full text Add to dashboard Cite

BackgroundPatients with type 2 diabetes mellitus (T2DM) have a high incidence of renal cell carcinoma (RCC) and high sodium glucose co-transporters 2 (SGLT2) expressions. The purpose of this study was to evaluate the anticancer activity of dapagliflozin as an SGLT2 inhibitor on RCC cell lines in vitro and in vivo.Material/MethodsqRT-PCR and Western blot were used to detect SGLT2 expression on different human renal cells. Then, flow cytometry and immunofluorescence were used to investigate the effects of dapagliflozin on cell cycle, apoptosis, and SGLT2 expression of CaKi-1 cells. Finally, a xenograft model and immunohistochemical staining were used to investigate the function of dapagliflozin in nude mice.ResultsWe proved that SGLT2 is highly expressed in RCC cell lines. We found that dapagliflozin exerts a higher cytotoxic effect on human RCC than on normal human renal cells, regulates the cell cycle and apoptosis, and reduces the glucose uptake and SGLT2 expression of CaKi-1 cells. Moreover, dapagliflozin inhibits tumor growth and reduces SGLT2 expression in vivo.ConclusionsOur results indicate that dapagliflozin has high efficiency and low toxicity and could be a new therapeutic target for RCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…An analogous mean age of 55 ± 15 years has also been reported by Sidharth et al, in 2011 among such patients in Nepal. Ray in 2016 reported similar mean age of 52.79 ± 13.47 years among Indian patients with renal cell carcinoma while Oglio reported it to be 59 ± 12 years in Brazilian such patients 13,14 .…”

Section: Discussionmentioning

confidence: 95%

Pax8 Expression and Its Associations in Primary Renal Cell Carcinoma: A Cross Sectional Study

Zamir

Akhtar

Waqar

et al. 2021

PAFMJ

View full text Add to dashboard Cite

Objective: To determine the frequency of PAX8 expression in cases of primary renal cell carcinoma (RCC) and its association with patient demographics and tumor type. Study Design: Cross sectional study. Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, from Jun 2016 to Jun 2017. Methodology: After ethics approval, 57 cases were selected by non probability consecutive sampling. Inclusion criteria was diagnosis of primary renal cell carcinoma of all histological types, in both genders, among adults aged >18 years. Exclusion criteria were poorly fixed specimens and metastatic renal cell carcinoma. The main outcome measure was PAX8 frequency in renal cell carcinoma. The secondary outcome measure was correlation of PAX8 expression with age, gender, tumor type and grade. Data was entered and analyzed on Statistical Package for the Social Sciences. Results: Out of 57 cases, majority were males 37, (64.9%). The mean age was 55.35 ± 12.60 years. Clear cell carcinoma was the most frequent histopathologic variant in 47 (81%) cases followed by papillary carcinoma in 6 (10.2%), chromophobe cell carcinoma 2 (3.5%), sarcomatoid renal carcinoma 1 (1.75%) and mucinous tubular and spindle cell carcinoma 1 (1.75%). PAX8 expression was positive in 52 (91.2%). No significant difference was found in the frequency of PAX8 expression across age (p=0.321), gender (p=1.00) and tumor type (p=1.00). There was significant difference seen across tumor grade p=0.03. Conclusion: PAX8 is an important additional diagnostic marker for renal cell carcinoma. It can be recommended for inclusion in immunohistochemical panel for diagnosis..............

show abstract

“…In the European Union, 84 000 new cases of RCC and 35 000 attributable deaths occurred in 2012 2. The incidence of RCC in Asian countries, particularly the Indian population, is lower than developed countries; however, data are limited 3. The reason for this could be that more tumours are picked up incidentally during abdominal imaging done for other reasons in developed countries.…”

Section: Discussionmentioning

confidence: 99%

Renal cell carcinoma presenting as a cutaneous horn and nodules on the gingiva and scalp

Georgy¹,

Mathuram

George

et al. 2017

BMJ Case Reports

View full text Add to dashboard Cite

A 63-year-old man presented with a pulsatile cutaneous horn on the nose and multiple angiomatous nodules on the gingiva and scalp, which appeared over 2 months. He had severe hypercalcaemia, lytic lesions in multiple bones and acute kidney injury. Excision biopsy from the gingival nodule showed a clear cell neoplasm. The bone marrow showed atypical cells with similar morphology. Imaging showed a 7 cmx7.5 cm mass at the upper pole of the left kidney with metastases to the bones, liver and lung. Immunohistochemistry was consistent with metastatic renal cell carcinoma. Renal cell carcinoma presenting as a cutaneous horn is extremely rare and to the best of our knowledge only one other case was found in the literature. There was visible regression in the size of the cutaneous horn and nodules following initiation of pazopanib therapy. However, he succumbed to his illness a month later.

show abstract

Clinical characteristics of renal cell carcinoma: Five years review from a tertiary hospital in Eastern India

Cited by 16 publications

References 1 publication

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma

Pax8 Expression and Its Associations in Primary Renal Cell Carcinoma: A Cross Sectional Study

Renal cell carcinoma presenting as a cutaneous horn and nodules on the gingiva and scalp

Contact Info

Product

Resources

About